What type of study is this?

The impact of ondansetron on clinical outcomes in cranial surgery patients: a propensity-matched analysis of retrospective data

View Full Paper

Ask AI

Bookmark

Ondansetron administration significantly reduced 28-day mortality in cranial surgery patients, supporting its potential benefit for recovery.
The analysis revealed a hazard ratio of 0.69 for 28-day mortality and 0.74 for 90-day mortality with ondansetron treatment.
Retrospective cohort study analyzed 2,297 patients, utilizing propensity score matching to adjust for baseline characteristics.
Findings highlight the therapeutic potential of ondansetron in improving postoperative outcomes in cranial surgery patients.

No takes yet. Share an insight, caveat, or question.

Retrospective cohort analysis shows ondansetron reduced 28-day and 90-day mortality in cranial surgery patients, suggesting clinical relevance.

Yun et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Retrospective cohort analysis shows ondansetron reduced 28-day and 90-day mortality in cranial surgery patients, suggesting clinical relevance.